early Alzheimer'
Conditions
Interventions
None listed
Sponsors
Osaka University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with probable/possible AD dementia or MCI due to AD-intermediate/high likelihood according to the 2011 NIA-AA clinical criteria. 2) Patients with a positive amyloid PET or cerebrospinal fluid (CSF) Ab42/40 ratio. 3) Patients who will receive lecanemab (consent can be obtained up to 26 weeks after administration even if the drug has been administered). 4) Patients who are at least aged 40 and less than 90 at the time of obtaining consent. 5) Individuals whose written consent to participate in the study has been obtained from them. Patients who meet the above criteria and their carers will be included.
Exclusion criteria
Exclusion criteria: 1) Persons with uncontrolled physical illnesses. 2) Persons who have another nationality or speak a language other than Japanese as their mother tongue. Patients who meet the above criteria and their carers are excluded from the eligible participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment Satisfaction Questionnaire for Medication (TSQM) score | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropsychiatric Inventory Questionnaire(NPI-Q) score, Everyday memory checklist(EMC) score, the presence of Amyloid Related Imaging Abnormalities(ARIA) | — |
Countries
Japan
Contacts
Public ContactYuto Satake
Osaka University Graduate School of Medicine Department of Psychiatry
Outcome results
None listed